The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis.
Blauvelt A, Chiricozzi A. · 2018
Read The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. by Blauvelt A, Chiricozzi A. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6244934.txt.
Introduction
Blauvelt and Chiricozzi review a signal protein in psoriasis. Psoriasis is a chronic immune skin disease. Its joint form is called psoriatic arthritis. A cytokine called IL-17 drives much of the disease. The review appeared in Clinical Reviews in Allergy and Immunology.
IL-17A comes from several cell sources in patients. Mast cells and T cells are among them. The protein acts on skin cells, vessel cells, and bone cells. It triggers antimicrobial peptides and more cytokines. Those effects fuel tissue inflammation and bone change. The IL-23 and IL-17 axis is now a prime drug target. New biologic drugs block these cytokines. They greatly improve skin and joint symptoms.
Catalog record
| CREATOR | Blauvelt A, Chiricozzi A. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis By Andrew Blauvelt, Andrea Chiricozzi Published in: Clinical Reviews in Allergy & Immunology DOI: 10.1007/s12016-018-8702-3 ABSTRACT Psoriasis is a chronic, immune-mediated, inflammatory disease that is pathogenically driven by proinflammatory cytokines. This article reviews the immunologic role of interleukin (IL)-17, the major effector cytokine in the pathogenesis of psoriatic disease, along with the rationale for targeting the IL-17 cytokine family (IL-17A, IL-17F, and IL-17 receptor A) in the treatment of psoriasis and psoriatic arthritis. Emerging evidence indicates that major sources of IL-17A in patients with psoriatic disease are mast cells, γδ T cells, αβ T cells, and innate lymphoid cells in lesional skin and synovial fluid. Within the skin and joints, IL-17A acts on cellular targets, including keratinocytes, neutrophils, endothelial cells, fibroblasts, osteoclasts, chondrocytes, and osteoblasts, to stimulate production of various antimicrobial peptides, chemokines, and proinflammatory and proliferative cytokines, which, in turn, promote tissue inflammation and bone remodeling. The critical importance of the IL-23/IL-17A axis to the pathogenesis of psoriatic disease has resulted in many new biologic treatments targeting these cytokines. These biologics dramatically improve skin and joint symptoms in patients with moderate-to-severe psoriasis and psoriatic arthritis. INTRODUCTION Psoriasis is a chronic, immune-mediated, inflammatory disease in which genetic and epigenetic changes result in a disease phenotype characterized by altered immune function, keratinocyte activation and hyperproliferation, and the development of erythematous, indurated, scaly plaques [1–4]. Psoriasis is driven by T cell activation associated with the secretion of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin (IL)-17A, IL-22, and interferon IFN-γ [1, 5]. The IL-23/IL-17 immunologic pathway plays an especially important role in promoting disease onset and perpetuation. Data from in vitro and clinical studies indicate that IL-17A, a critical effector cytokine in this pathway, principally drives changes within affected tissues [6–11]. Direct evidence supporting the central role of IL-17A in psoriasis includes upregulation of IL-17A and related genes in lesional and non-lesional skin of patients with psoriasis and production of IL-17A by cells associated with psoriasis [6, 8, 12]. In an in vitro study using reconstituted human epidermal sheets, IL-17A stimulated greater transcriptional activation than IL-22 or IFN-γ, correlating with the psoriasis transcriptome [13]. IL-17 also increases expression of the antimicrobial peptide LL37, a psoriasis autoantigen that promotes production of proinflammatory cytokines, and C-X-C motif chemokine ligand 1 (CXCL1) [14, 15]. This, in turn, drives expansion of ADAMTS-like protein 5 (ADAMTSLP5), another psoriasis autoantigen, causing additional expression of IL-17A and IFN-γ [15, 16]. In addition to IL-17A, the IL-17 family consists of five other members (IL-17B-F) [17–23]. Within this family, IL-17A, IL-17C, and IL-17F are implicated in psoriasis pathogenesis as their expression is increased up to eightfold in psoriatic lesions [6, 24, 25]. Although there is more IL-17C and IL-17F in psoriatic lesions, IL-17A is the most biologically active (up to 30-fold more active than IL-17F) [10, 24]. While these three cytokines act on keratinocytes to stimulate production of proinflammatory cytokines and chemokines, the exact role of IL-17C in psoriasis pathogenesis is poorly understood [6, 25]. Despite high levels of IL-17C in psoriatic lesions, IL-17C has less impact on keratinocyte gene expression than IL-17A, IFN-γ, and TNF-α, suggesting that IL-17A is more important than IL-17C in promoting cutaneous inflammation [26]. Therapies targeting IL-17A alone are known to modulate gene expression of various cytokines and chemokines, and effectively clear psoriatic lesions [6, 27–29]. More specifically, 2 weeks of IL-17A inhibition resulted in normalization of 765 genes, whereas TNF-α inhibition resulted in the normalization of far fewer genes (< 200) [30, 31]. In this article, the immunologic role of IL-17 in psoriasis and psoriatic arthritis (PsA) pathogenesis, including its role in innate and adaptive immunity, and the rationale for targeting IL-17A, IL-17F, and IL-17 receptor A in the treatment of psoriasis and PsA, are reviewed. CELLULAR SOURCES OF INTERLEUKIN-17 IN INNATE AND ADAPTIVE IMMUNITY For several years, it was hypothesized that the primary source of IL-17A in psoriasis was T helper 17 (Th17) cells. Specifically, human Th17 cells differentiate from naïve T cells under the influence of TGF-β1 and proinflammatory cytokines (IL-1β, IL-6, and/or IL-21) [32, 33]. Differentiated human Th17 cells are stimulated to produce cytokines by IL-23, which also promotes the survival of Th17 cells [34, 35]. Th17 cells produce a wide variety of cytokines in addition to IL-17A, including IL-17F, IL-21, IL-22, IL-26, and TNF-α [34, 36]. Additionally, increased numbers of Th17 cells are found in the blood and affected skin of patients with psoriasis and in the blood and synovial fluid of patients with PsA [11, 37]. Recently, however, there has been a paradigm shift in the understanding of cellular sources of IL-17A in psoriasis and PsA. Increasingly, data indicate that additional important cellular sources of IL-17A are mast cells, γδ T cells, αβ T cells, and innate lymphoid cells (ILCs; Table 1) [38, 39, 47].Table 1Cellular sources of IL-17 [38–46]Cell typeDescriptionγδ T cells• Potent source of innate IL-17 produced independently of IL-6• Properties are similar to Th17 cells (e.g., expression of CCR6, IL-23R, and RORγt); these cells also express TLR1, TLR2, and dectin-1• Levels of IL-17-producing γδ T cells increase during some types of bacterial infections• Different subsets of γδ T cells in the thymus produce either IL-17 or IFN-γ• Major source of gut-protective IL-17, which acts independently from IL-23αβ T cells• Recent data indicate CD4/CD8 double-negative αβ T cells produce IL-17 in psoriatic inflammation• These cells respond to IL-23 to produce IL-17• These cells likely express RORγt and CCR6Neutrophils• Rich source of IL-17 in psoriasis• IL-17 is held and released by neutrophils via extracellular trap formation• Conflicting data have been reported on whether IL-17 mRNA is present in neutrophilsMast cells• In response to trauma or infection, preformed inflammatory mediators, including IL-17, are released from mast cells via granulation or mast cell extracellular trap cell death• Mast cells also express IL-17 mRNA and produce IL-17A and IL-17 receptor AILC3s• Subset of ILCs defined by their capacity to produce IL-17A and/or IL-22• Found in lesional and non-lesional skin, and in peripheral blood in patients with psoriasis, and in synovial fluid in patients with PsAiNKT cells• Cells that express a restricted TCR that recognizes glycolipid antigens• May provide an alternative source of IL-17 when IL-6 is not present to stimulate Th17 cells• IL-17+ cells express IL-23R and IL-1R1Adaptive Th17 cells• A subset of activated CD4+ T helper cells that produce high levels of IL-17A, IL-17F, IL-22, and IFN-γ, and express IL-23R• CD4+ TCRα/β+ Th17 cells are a well-characterized source of IL-17 that play a key role in immune inflammatory responsesNatural Th17 cells• Subset of thymic Th17 cells that acquire effector function prior to peripheral antigen exposure• These cells have different TCR gene usage and signaling properties compared with conventional Th17 cellsTc17 cells• Subset of CD8+ cells that produces IL-17• May play a role in pathogenic skin and joint inflammation in psoriasis and PsA, respectivelyCCR6, C-C chemokine receptor type 6; CD, cluster of cell differentiation; IFN, interferon; IL, interleukin; IL-1R1, interleukin-1 receptor, type 1; IL-23R, interleukin-23 receptor; ILC, innate lymphoid cell; iNKT, invariant natural killer T; PsA, psoriatic arthritis; ROR, retinoic orphan receptor; Tc17, IL-17-expressing CD8+ T cells; TCR, T cell receptor; Th17, T helper 17; TLR, toll-like receptor It was long